Understanding the benefits and harms of oxygen therapy: response to comments by Akca

Affiliations

¹ Université Angers, Angers, France. piasfar@chu-angers.fr.
² Bloomsbury Institute of Intensive Care Medicine, University College London, London, UK.
³ Institut für Anästhesiologische Pathophysiologie und Verfahrensentwicklung, Universitätsklinikum, Ulm, Germany.

Comment

Pierre Asfar et al. Intensive Care Med. 2015 Oct.

. 2015 Oct;41(10):1875.

doi: 10.1007/s00134-015-3995-7. Epub 2015 Jul 28.

¹ Université Angers, Angers, France. piasfar@chu-angers.fr.
² Bloomsbury Institute of Intensive Care Medicine, University College London, London, UK.
³ Institut für Anästhesiologische Pathophysiologie und Verfahrensentwicklung, Universitätsklinikum, Ulm, Germany.

No abstract available

Comment on

Understanding the benefits and harms of oxygen therapy.
Asfar P, Singer M, Radermacher P. Asfar P, et al. Intensive Care Med. 2015 Jun;41(6):1118-21. doi: 10.1007/s00134-015-3670-z. Epub 2015 Jan 30. Intensive Care Med. 2015. PMID: 25634474 No abstract available.
Hyperoxia: is it a biomarker for mortality?
Akca O. Akca O. Intensive Care Med. 2015 Oct;41(10):1873-4. doi: 10.1007/s00134-015-3975-y. Epub 2015 Jul 28. Intensive Care Med. 2015. PMID: 26215680 No abstract available.